MPTP/MPP+ 诱导神经元凋亡的机制研究

1982年人们发现1-甲基-4-苯基-1,2,3,6-四氢吡啶(MPTP)能诱发PD,它的有效成分是1-甲基-4-苯基吡啶离子(MPP+)。目前,MPTP/MPP+广泛的被用作诱导PD实验模型的有效药物,可诱导神经元细胞发生凋亡性死亡。MPTP/MPP+诱导细胞凋亡的机制牵涉Bcl-2、p53、caspase家族、JNK通路、ERK通路和PARP等多种机制,它们共同参与了MPTP/MPP+诱导的细胞凋亡的调控和执行阶段。本文主要综述MPTP/MPP+诱导的神经元细胞凋亡机制。     

MPTP帕金森病动物模型研究进展

用神经毒素1-甲基-4-苯基-1,2,3,6-四氢吡啶(MPTP)制备的动物模型,无论在神经生化和病理组织学特征,还是在运动行为表现方面都酷似人帕金森病(PD),是目前研究PD的理想模型。对MPTP动物模型发病机制等方面的深入研究将有助于PD的防治。     

CUL1基因对MPP+诱导的SH-SY5Y细胞存活和NLRP3炎症体通路的影响

摘要 目的：探究Cullin1（CUL1）基因对1-甲基-4-苯基吡啶离子（MPP+）诱导的SH-SY5Y细胞存活和核苷酸结合寡聚化结构域样受体3（NLRP3）炎症体通路的影响。方法：（1）将SH-SY5Y细胞分为NC组、NC-sh组、CUL1-sh组、NC-OE组和CUL1-OE组。使用Lipofectamine 2000试剂对细胞转染相应的慢病毒。（2）将SH-SY5Y细胞分为Control组、MPP+组和MPP++CUL1-OE组。MPP+组和MPP++CUL1-OE组细胞使用1 mmol/L的MPP+处理48 h,Control组细胞正常培养。通过MTT法检测细胞增殖,通过Annexin V-FITC/PI双染色法和TUNEL染色法检测细胞凋亡,通过qRT-PCR检测CUL1的mRNA水平,通过Western blot检测CUL1、NLRP3、凋亡相关斑点样蛋白（ASC）、cleaved caspase-1、白细胞介素（IL）-1β和IL-18蛋白水平。通过ELISA法检测细胞培养上清液中IL-1β和IL-18水平。结果：（1）与NC组和NC-sh组比较,CUL1-sh组CUL1的mRNA和蛋白相对表达量降低,相对细胞活力降低,Annexin V-FITC/PI阳性率和TUNEL阳性率升高,NLRP3、ASC、cleaved caspase-1、IL-1β和IL-18蛋白相对表达量以及细胞培养上清液中IL-1β和IL-18水平升高（P<0.05）。与NC组和NC-OE组比较,CUL1-OE组CUL1的mRNA和蛋白相对表达量升高,相对细胞活力升高,Annexin V-FITC/PI阳性率和TUNEL阳性率降低,NLRP3、ASC、cleaved caspase-1、IL-1β和IL-18蛋白相对表达量以及细胞培养上清液中IL-1β和IL-18水平降低（P<0.05）。（2）与Control组比较,MPP+组CUL1的mRNA和蛋白相对表达量降低,相对细胞活力降低,Annexin V-FITC/PI阳性率和TUNEL阳性率升高,NLRP3、ASC、cleaved caspase-1、IL-1β和IL-18蛋白相对表达量以及细胞培养上清液中IL-1β和IL-18水平升高（P<0.05）。与MPP+组比较,MPP++CUL1-OE组CUL1的mRNA和蛋白相对表达量升高,相对细胞活力升高,Annexin V-FITC/PI阳性率和TUNEL阳性率降低,NLRP3、ASC、cleaved caspase-1、IL-1β和IL-18蛋白相对表达量以及细胞培养上清液中IL-1β和IL-18水平降低（P<0.05）。结论：CUL1可能通过抑制NLRP3炎症体激活促进MPP+诱导的SH-SY5Y细胞存活。     

MPTP对小鼠帕金森病造模条件探讨

目的观察不同剂量1-甲基-4-苯基-1,2,3,6-四氢吡啶(MPTP)对小鼠行为学及脑黑质酪氨酸羟化酶、纹状体多巴胺含量的影响,探讨MPTP致帕金森病(Parkinson′s disease,PD)样小鼠模型的最佳条件。方法C57BL小鼠分别给与MPTP不同剂量处理,测定各组小鼠爬竿时间检测动物运动协调性,应用免疫组化方法和高效液相法观察不同模型组多巴胺能神经元的变化。结果模型组各组均出现不同程度爬竿时间延长,酪氨酸羟化酶阳性细胞数减少和多巴胺含量减少。结论MPTP处理可造成小鼠的帕金森病样症状,在此种动物模型中,应根据科研目的选择MPTP的应用剂量和给药途径。     

中脑多巴胺A9、A10神经元在MPTP损伤中敏感性的差异

自从科学家发现1-甲基-4-苯基-1,2,3,6-四氢吡啶（MPTP）选择性损伤中脑黑质致密区（A9）多巴胺神经元通路以来,用这种神经毒素诱导的帕金森病（PD）模型被广泛应用于PD的研究。然而同为DA能神经元的中脑一边缘一皮层的DA（A10）系统是否也遭到同样损伤呢？     

迷迭香酸对MPTP诱导的多巴胺神经元损伤的保护作用

多巴胺神经元损伤是PD发病的重要机制,本文利用1-甲基-4-苯基-1,2,3,6-四氢吡啶(1-methyl-4-pheyl-1,2,3,6-tetrahydrophridine,MPTP)诱导多巴胺神经元损伤,在诱导损伤前给予不同剂量迷迭香酸处理,采用细胞活性检测试剂盒(CCK-8)检测神经元的活性;活性氧(reactive oxygen species,ROS)检测试剂盒检测神经元ROS水平;Western blot(WB)检测神经元凋亡相关蛋白caspase-3和cleaved caspase-3的表达,研究迷迭香酸(Rosemarinic acid,RA)对MPTP诱导的神经元损伤的保护作用及可能机制。结果显示,MPTP处理可使多巴胺神经元活力显著降低(P0.05),ROS水平和cleaved caspase-3表达显著升高(P0.01);迷迭香酸预处理(40μmol/L和20μmol/L)可逆转MPTP诱导的多巴胺神经元活力降低,抑制MPTP诱导的多巴胺神经元ROS和cleaved caspase-3升高(P0.05,P0.01)。迷迭香酸预处理对MPTP诱导的多巴胺神经元损伤具有保护作用,其机制可能与抑制ROS释放,阻止caspase-3异常激活有关。     

尼古丁对帕金森病小鼠多巴胺能神经元的保护作用

目的：观察尼古丁对多巴胺能神经元的作用并探讨其作用机制。方法：采用1-甲基-4-苯基-1,2,3,6-四氢吡啶（1-methyl-4-phenyl—1,2,3,6-tetrahydmpyridine,MPTP）小鼠模型,通过行为学方法、免疫组织化学、电镜观察尼古丁预处理对帕金森病（parkinson’s disease,PD）小鼠的影响。结果：尼古丁预处理可以明显缩短PD小鼠的爬杆时间,提高悬挂的得分。免疫组化结果显示尼古丁显著减少多巴胺（doparnine,DA）能神经元变性（P〈0．01）和γ-氨基丁酸（γ-aminobutyric acid,GABA）能神经元的脱失（P〈0．05）,并可减轻尾核超微结构的损伤。结论：尼古丁可减轻MPTP小鼠多巴胺能神经元的损伤,对多巴胺能神经元有保护作用。     

1-甲基-4-苯基-吡啶盐致多巴胺能细胞系MES23.5的死亡机制

通过测定环境毒素1-甲基-4-苯基-吡啶盐(MPP )作用于多巴胺能细胞系MES23．5后细胞存活率的变化及细胞线粒体膜电位(△ψM)、活性氧(ROS)、羟自由基、超氧化物岐化酶(SOD)的变化,发现MPP^ 作用于多巴胺能细胞系MES23．5,可导致细胞存活率显著性减少,浓度达到200mol／L以上后,细胞存活率的下降呈时间与MPP^ 浓度依赖;以200μmol/L MPP^ 作用细胞6∽48h后,△ψM逐渐下降、ROS、羟自由基逐渐增加,48h后SOD开始显著性减少。结果表明早期线粒体能量代谢障碍和膜电位变化导致ROS(尤其是羟自由基)含量增加是MPP^ 导致多巴胺能细胞氧化应激的原因,而细胞内自由基的清除机制受损,则最终导致细胞变性死亡。     

低分子肝素对MPTP帕金森小鼠的治疗作用及可能机制

目的：研究1．甲基4-苯基-1,2,3,6-四氢吡啶（1-methy-4-phenyl-1,2,3,6-tetrahy-dropyridine,MPTP）帕金森病（PD）模型中小胶质细胞的激活情况,探讨低分子肝素对MPTP导致的小胶质细胞活化的抑制作用。方法：C57BL随机分成正常对照组、MPTP组、低分子肝素＋MPTP组。MPTP组腹腔注射MPTP（30mg／kgx7d）同时腹部皮下注射生理盐水,低分子肝素＋MPTP组在注射MPTP同时腹部皮下注射低分子肝素（1501U／kg·12hx7d）。各组于末次给药后予行为学测试,7d后免疫组化检测酪氨酸羟化酶（TyrosineHydroxylase,TH）阳性细胞。镀银染色观察小胶质细胞激活情况。结果：MPTP组较低分子肝素＋MPTP组爬竿时间明显延长,并出现更多非随意动作。低分子肝素＋MPTP组黑质部位TH阳性细胞数量高于MPTP组。MPTP组活化的小胶质细胞数量高于低分子肝素＋MPTP组。结论：低分子肝素通过抑制小胶质细胞的激活减少MPTP帕金森小鼠多巴胺能神经元的损伤,提示低分子肝素可能有延缓PD进程的作用。     

毕赤酵母表达的neurturin对恒河猴帕金森氏病模型中黑质多巴胺能神经元的保护作用

帕金森氏病(PD)是由于多巴胺能神经元变性、坏死,导致黑质-纹状体系统的多巴胺含量下降而引起的一种神经系统退行性疾病,目前还没有一种很好的方法能使之治愈.Neurturin（NTN）能特异地作用于中脑多巴胺能神经元,对该类神经元具营养和保护作用.经静脉注射1-甲基-4-苯基-1,2,3,6-四氢吡啶(MPTP)诱导恒河猴产生帕金森氏病模型,并在NTN治疗组,注射MPTP之前48 h脑室内注射重组毕赤酵母表达的人NTN 1 mg. 结果表明：模型组猴均逐渐出现了PD症状,而NTN治疗组猴,PD症状比较轻或不明显;荧光分光光度法测定MPTP模型组猴黑质、壳核和尾状核多巴胺（DA）、5-羟色胺（5-HT）和5-羟吲哚乙酸（5-HIAA）的含量结果与正常对照组相比均显著降低,NTN治疗组猴的黑质、壳核和尾状核中的DA、5-HT和5-HIAA与对照组相比无显著性差异,而与模型组相比,DA、5-HT和5-HIAA含量均明显增加;光镜检查MPTP模型组猴黑质神经元细胞明显脱失,而NTN治疗组猴黑质神经元细胞丢失不明显,与正常对照组猴无差别.上述结果表明,制备的重组人NTN在恒河猴体内能保护中脑黑质多巴胺能神经元不受MPTP的损伤,使其DA含量及多巴胺能神经元维持正常,在MPTP存在下没有发生PD症状.     

葛根素对帕金森病细胞模型的保护作用研究

目的:研究葛根素对帕金森病细胞模型的保护作用及其具体的作用机理.方法:用0.16mM的MPP+处理PC12细胞48h建立帕金森病细胞模型.实验分为对照组、损伤组和保护组,损伤组用MPP+(0.16mM)处理PC12细胞;保护组用葛根素提前预处理PC12细胞1h,后加MPP+.检测PC12细胞存活率、Caspase-3活性及ERβ的转录活性.结果:葛根素能够抑制caspase-3的激活,且其依赖于ERβ的表达,雌激素受体拮抗剂ICI182,780可阻断上述效应;其次葛根素可提高ERβ的转录活性.结论:葛根素对MPP+诱导损伤的PC12细胞具有抗细胞凋亡的保护作用,且具体的作用机理可能依赖于ERβ介导的经典的基因组作用模式.     

Acetyl-L-carnitine prevents total body hydroxyl free radical and uric acid production induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the rat

Acetyl-L-carnitine (ALCAR) is intimately involved in the transport of long chain fatty acids across the inner mitochondrial membrane during oxidative phosphorylation. ALCAR also has been reported to attenuate the occurrence of parkinsonian symptoms associated with 1-methyl-1,2,3,6-tetrahydropyridine (MPTP) in vivo, and protects in vitro against the toxicity of the neurotoxic 1-methyl-4-phenylpyridinium (MPP+) metabolite of MPTP. The mechanism for these protective effects remains unclear. ALCAR may attenuate hydroxyl (HO*) free radical production in the MPTP/MPP+ neurotoxic pathway through several mechanisms. Most studies on MPTP/MPP+ toxicity and protection by ALCAR have focused on in vivo brain chemistry and in vitro neuronal culture studies. The present study investigates the attenuative effects of ALCAR on whole body oxidative stress markers in the urine of rats treated with MPTP. In a first study, ALCAR totally prevented the MPTP-induced formation of HO* measured by salicylate radical trapping. In a second study, the production of uric acid after MPTP administration-a measure of oxidative stress mediated through xanthine oxidase-was also prevented by ALCAR. Because ALCAR is unlikely to be a potent radical scavenger, these studies suggest that ALCAR protects against MPTP/MPP+-mediated oxidative stress through other mechanisms. We speculate that ALCAR may operate through interference with organic cation transporters such as OCTN2 and/or carnitine-acylcarnitine translocase (CACT), based partly on the above findings and on semi-empirical electronic similarity calculations on ALCAR, MPP+, and two other substrates for these transporters.     

ERK活化对哮喘大鼠气道重塑及CyclinD1表达的影响

目的探讨细胞外信号调节蛋白激酶（ERK）对哮喘大鼠气道重塑及CyclinD1表达的作用。方法原代培养大鼠的平滑肌细胞（ASMCs）,给予ERK激动剂表皮生长因子EGF和抑制剂PD98059干预ASMCs生长,依处理方式不同分为5组：（1）正常对照组（2）哮喘对照组;（3）E组：EGF20 ng/mL;（4）P＋E组,PD98059 10μmol/L1 h后添加EGF 20 ng/mL;（5）PD组,PD98059 10μmol/L。采用四甲基偶氮唑盐（MTT）法检测气道平滑肌细胞（ASMCs）增殖能力,流式细胞术（FCM）测定细胞周期和cyclinD1的蛋白含量,RT-PCR方法检测cyclinD1mRNA表达水平。结果（1）与哮喘对照组比较,E组ASMCs S＋G2/M期比例、吸光度A值、cyclinD1蛋白阳性表达率和cyclinD1 mRNA的A值均显著升高,PD组均显著降低（P〈0.05）。P＋E组与哮喘对照在此4项指标上比较无明显差异。（2）哮喘（对照组、E组、PD组和P＋E组）组与正常对照组,其S＋G2/M期比例、吸光度A值、cyclinD1蛋白和cyclinD1 mRNA的表达均显著增高（P〈0.05）。结论ERK活性促进哮喘大鼠ASMCs的增殖,增加cyclinD1在哮喘平滑肌细胞中的表达,导致气道重塑的形成,提示ERK可能对CyclinD1的表达具有调节作用。     

神经元型一氧化氮合酶在Ⅱ组代谢型谷氨酸受体介导的脑缺血耐受中的作用

目的：探讨神经元型一氧化氮合酶（nNOS）催化产生的一氧化氮（NO）在Ⅱ组代谢型谷氨酸受体（mGluR2／3）介导的脑缺血预处理（CIP）保护机制中的作用。方法：36只永久凝闭椎动脉的SD大鼠随机分为6组（n=6）：sham、CIP、损伤性缺血、CIP4-损伤性缺血、MqPG＋CIP和MTPG＋CIP＋损伤性缺血组。采用硫堇染色和免疫组化观察海马CA1区迟发性神经元死亡（DND）和nNOS表达的变化。结果：与Sham组相比,CIP组海马nNOS表达出现一定程度的上调,而损伤性脑缺血组则出现nNOS表达的明显上调,预先给与CIP可一定程度上防止损伤性脑缺血所致的nNOS表达的过度升高。在MTPG4-CIP组,预先侧脑室注射mGluR2／3阻断剂MTPG,可阻断CIP引起的nNOS表达增加,但对神经元的存活无影响。而在MTPG＋CIP＋损伤性缺血组中,出现大量锥体神经元DND,同时nNOS的表达较MTPG＋CIP组明显增加,该增加为损伤性脑缺血所致,而非MTPG的作用。结论：nNOS催化产生的NO作为mGluR2／3的下游分子参与脑缺血预处理过程中mGluR2／3介导的脑缺血耐受的形成。     

Kynurenic acid attenuates MPP(+)-induced dopaminergic neuronal cell death via a Bax-mediated mitochondrial pathway

Kynurenic acid (KYNA), a tryptophan metabolite in the kynurenine pathway, is protective against various insults. However, the molecular mechanism of this protective effect has not been identified. In this study, we examined the protective effects of KYNA against 1-methyl-4-phenylpyridinium (MPP(+)), the best-characterized toxin inducing pathological changes resembling Parkinson's disease (PD), using SH-SY5Y and SK-N-SH human neuroblastoma cells. Pre-treatment of KYNA attenuated MPP(+)-induced neuronal cell death in SH-SY5Y and SK-N-SH cells. MPP(+)-induced cell death was preceded by increases in Bax expression and mitochondrial dysfunction, such as collapse of mitochondrial membrane potential (DeltaPsi(m)), release of cytochrome c from mitochondria into the cytoplasm, and increases in caspase-9/-3 activities. KYNA effectively inhibited all of these mitochondrial apoptotic processes. Our results indicate that KYNA plays a protective role by down-regulating Bax expression and maintaining mitochondrial function in MPP(+)-induced neuronal cell death, and suggest that KYNA may have therapeutic potential in PD.     

TRPC1 inhibits apoptotic cell degeneration induced by dopaminergic neurotoxin MPTP/MPP

Disturbances in Ca²⁺ homeostasis have been implicated in a variety of neuropathological conditions including Parkinson's disease (PD). However, the importance of store-operated Ca²⁺ entry (SOCE) channels in PD remains to be investigated. In the present study, we have scrutinized the significance of TRPC1 in 1-methyl-4-phenyl-1,2,3,6-tetrahyrdro-pyridine (MPTP)-induced PD using C57BL/6 animal model and PC12 cell culture model. Both sub-acute and sub-chronic treatments of MPTP significantly reduced TRPC1, and tyrosine hydroxylase levels, but not TRPC3, along with increased neuronal death. Furthermore, MPTP induces mitochondrial dysfunction, which was associated with reduced mitochondrial membrane potential, decreased level of Bcl₂, Bcl-xl, and an altered Bcl-xl/Bax ratio thereby initiating apoptosis. Importantly, TRPC1 overexpression in PC12 cells showed significant protection against MPP⁺ induced neuronal apoptosis, which was attributed to the restoration of cytosolic Ca²⁺ and preventing loss of mitochondrial membrane potential. Silencing of TRPC1 or addition of TRPC1 channel blockers decreased mitochondrial membrane potential, whereas activation of TRPC1 restored mitochondrial membrane potential in cells overexpressing TRPC1. TRPC1 overexpression also inhibited Bax translocation to the mitochondria and thereby prevented cytochrome c release and mitochondrial-mediated apoptosis. Overall, these results provide compelling evidence for the role of TRPC1 in either onset/progression of PD and restoration of TRPC1 levels could limit neuronal degeneration in MPTP mediated PD.     

Effects of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine and 1-Methyl-4-Phenylpyridinium Ion on Activities of the Enzymes in the Electron Transport System in Mouse Brain

The effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridinium ion (MPP+) on activities of enzyme complexes in the electron transport system were studied using isolated mitochondrial preparations from C57BL/6J mouse brains. Both MPTP and MPP+ dose-dependently inhibited activity of NADH-ubiquinone oxidoreductase (EC 1.6.5.3). The inhibition was reversible. Preincubation of freeze-thawed mitochondria with MPTP or MPP+ had no effect on the inhibition; however, when nonfrozen mitochondria were used, NADH-ubiquinone oxidoreductase activity was reduced to 46% of that in the nonincubated sample after a 5-min preincubation with MPTP and to 77% of that in the nonincubated sample after a 5-min preincubation with MPP+. Kinetic analyses revealed that inhibition of MPTP was noncompetitive and that of MPP+ uncompetitive with respect to NADH. On the other hand, inhibition of MPTP was uncompetitive and that of MPP+ noncompetitive with respect to ubiquinone. Succinate-ubiquinone oxidoreductase (complex II), dihydroubiquinone-cytochrome c oxidoreductase (complex III), and ferrocytochrome c-oxygen oxidoreductase (EC 1.9.3.1) activities were either slightly inhibited or not inhibited by MPTP or MPP+. The significance of these findings is discussed in relation to the mechanism of MPTP-induced neuronal degeneration.     

星形胶质细胞在MPTP帕金森小鼠脑内的变化研究

目的：研究神经毒素1-甲基-4-苯基-1,2,3,6-四氢吡啶（1-methy-4-phenyl-1,2,3,6-tetrahy-dropyridine,MPTP）对小鼠脑内星形胶质细胞及肿瘤坏死因子-α（Tunlomecrosis factor alpha,TNF-α）的影响,了解MPTP致帕金森病发病机制。方法：将神经毒素MPTP注入C57BL／6小鼠腹腔内,制备帕金森病动物模型。观察注药后小鼠行为学变化,免疫组化检测各时间点多巴胺能神经元缺失和星形胶质细胞增生与激活情况,以及TNF-α表达水平的变化。结果：MPTP组黑质多巴胺（dopamine,DA）能神经元的数量随注射天数增加而持续减少,星形胶质细胞数量明显增高,GFAP及TNF-α在模型组黑质内有中强阳性表达,与对照组相比差异有统计学意义（P〈0．05）。结论：MPTP可诱导星形胶质细胞的激活和增生,启动脑内炎症反应而介导DA神经元死亡。     

线粒体通透性转换孔在缺血预处理脑保护中的作用及机制

目的：线粒体通透性转换孔通透性改变是导致缺血再灌注损伤的原因,线粒体功能的致命性改变最终引起细胞凋亡,本研究旨在观察线粒体通透性转换孔（mitochondrial permeability transition pore,MPTP）在缺血再灌注及缺血预处理脑保护中的作用;方法：将体外培养8天的海马神经元细胞分为五组,正常对照组（A组）,缺血再灌注组（B组）,缺血预处理＋缺血再灌注组（C组）,苍术苷＋缺血再灌注组（D组）,缺血预处理＋苍术苷＋缺血再灌注组（E组）。使用流式细胞术检测各组细胞凋亡率,罗丹明123染色流式细胞术检测线粒体膜电位,Western-blot检测Bcl-2,Bax的表达。结果：与A组比较,其余四组线粒体膜电位均降低,神经元凋亡率升高（P〈0．05）;与B组比较,c组线粒体膜电位升高,神经元凋亡率升高,Bcl-2表达上调,Bax表达下调（P〈0．05）;与c组比较,E组粒体膜电位降低,神经元凋亡率升高,Bcl．2表达下调,Bax表达上调（P〈0．05）。结论：我们在细胞及分子生物学水平对MPTP及缺血预处理的研究后发现,缺血预处理能有效减轻海马神经元缺血再灌注损伤,抑制缺血再灌注后神经细胞凋亡,其机制与抑制MPTP的开放有关。